Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer

Expert Opinion on Drug Metabolism and Toxicology · Published 2026-07-03 · DOI 10.1080/17425255.2026.2710110

Authors (3)

Elaria Abdy, Jean-Pierre Betancourt, Supratik Kar

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Abdy, E., Betancourt, J., Kar, S. (2026). Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer. Expert Opinion on Drug Metabolism and Toxicology. https://doi.org/10.1080/17425255.2026.2710110

Related articles

• Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance · Expert Opinion on Drug Metabolism and Toxicology · 2025 · Same journal
• Microbiome-driven PKs: redefining drug metabolism beyond host enzymes · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Combined oral contraceptives and pharmacokinetic drug interactions: impact on efficacy and safety · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Predicting the potential for organic cation transporter 1-mediated drug–drug interactions with fenoterol by amitriptyline, fluoxetine, selegiline, metformin, and verapamil · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Pharmacokinetics and safety of the combination of KL130008 and methotrexate in rheumatoid arthritis patients: a multicenter, open-label phase Ib trial · Expert Opinion on Drug Metabolism and Toxicology · 2025 · Same journal
• Evaluation of the drug-drug interaction between low-dose methotrexate and short-term use of non-steroidal anti-inflammatory drugs · Expert Opinion on Drug Metabolism and Toxicology · 2025 · Same journal
• GLP-1RA PHARMACOKINETICS AND CLINICAL EFFECTS: FOCUS ON CARDIAC, VASCULAR, AND GLOMERULAR STRUCTURES · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Modifying Hy’s Law and eDISH for the modern idiosyncratic DILI era · Expert Opinion on Drug Metabolism and Toxicology · 2025 · Same journal
• Exploring the influence of sex on idiosyncratic DILI: impact on risk assessment · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Complex in vitro model developers’ perspective on advanced hepatic in vitro culture methods for predictive drug safety · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal